Table 5. Multivariate association between adherence and recurrence adjusted for covariates.
| |
Unadjusted |
Adjusted |
||||
|---|---|---|---|---|---|---|
| Predictor | HR | 95% CI | P-value | HR | 95% CI | P-value |
|
Adherence | ||||||
| ⩾0.8 | 1 | 1 | ||||
| <0.8 |
1.689 |
1.371–2.082 |
<0.0001 |
1.219 |
0.970–1.531 |
0.089 |
|
Cumulative adherencea | ||||||
| ⩾5 | 1 | — | — | 1 | — | — |
| 4 | 1.079 | 0.724–1.607 | 0.708 | 1.653 | 1.136–2.404 | 0.009 |
| 3 | 1.730 | 1.179–2.539 | <0.005 | 2.667 | 1.838–3.868 | <0.0001 |
| 2 | 3.357 | 2.304–4.889 | <0.0001 | 4.567 | 3.160–6.601 | <0.0001 |
| ⩽1 |
3.353 |
2.329–4.827 |
<0.0001 |
5.860 |
4.074–8.429 |
<0.0001 |
|
Menopause | ||||||
| Pre | 1 | — | — | 1 | — | — |
| Peri | 0.292 | 0.128–0.667 | 0.004 | 0.341 | 0.148–0.785 | 0.011 |
| Post | 0.787 | 0.618–1.001 | 0.051 | 0.812 | 0.592–1.114 | 0.197 |
| Unknown |
0.428 |
0.329–0.557 |
<0.0001 |
0.400 |
0.291–0.551 |
<0.0001 |
|
Age | ||||||
| 1 year |
1.002 |
0.995–1.008 |
0.621 |
1.004 |
0.995–1.012 |
0.414 |
|
SIMD quintile | ||||||
| 1 | 1 | — | — | 1 | — | — |
| 2 | 1.093 | 0.792–1.508 | 0.546 | 1.105 | 0.799–1.529 | 0.546 |
| 3 | 1.124 | 0.826–1.531 | 0.166 | 1.247 | 0.913–1.702 | 0.166 |
| 4 | 0.977 | 0.738–1.293 | 0.755 | 1.046 | 0.788–1.389 | 0.755 |
| 5 | 0.809 | 0.596–1.099 | 0.346 | 0.861 | 0.631–1.175 | 0.346 |
| Unknown |
0.711 |
0.287–1.761 |
0.761 |
0.868 |
0.347–2.168 |
0.761 |
|
Tumour stage | ||||||
| T1 | 1 | — | — | 1 | — | — |
| T2 | 2.643 | 2.003–3.488 | <0.0001 | 2.264 | 1.702–3.011 | <0.0001 |
| T3 | 4.697 | 3.212–6.870 | <0.0001 | 2.514 | 1.671–3.782 | <0.0001 |
| T4 | 4.540 | 3.252–6.337 | <0.0001 | 1.980 | 1.352–2.902 | <0.0001 |
| Unknown |
1.609 |
1.231–2.103 |
<0.0001 |
1.284 |
0.956–1.725 |
0.097 |
|
Nodal stage | ||||||
| N0 | 1 | — | — | 1 | — | — |
| N1 | 3.131 | 2.502–3.918 | <0.0001 | 1.966 | 1.547–2.498 | <0.0001 |
| N2 | 3.745 | 2.377–5.901 | <0.0001 | 1.712 | 1.024–2.862 | 0.040 |
| Unknown |
0.965 |
0.771–1.208 |
0.756 |
1.378 |
0.943–2.015 |
0.098 |
|
Metastases stage | ||||||
| M0 | 1 | — | — | 1 | — | — |
| M1 | 3.212 | 2.156–4.785 | <0.0001 | 1.166 | 0.738–1.843 | 0.510 |
| Unknown |
0.834 |
0.676–1.029 |
0.090 |
0.954 |
0.678–1.343 |
0.788 |
|
Tumour grade | ||||||
| G1 | 1 | — | — | 1 | — | — |
| G2 | 1.948 | 1.319–2.878 | 0.001 | 1.373 | 0.924–2.039 | 0.117 |
| G3 | 3.867 | 2.632–5.682 | <0.0001 | 2.243 | 1.506–3.340 | <0.0001 |
| Unknown |
2.307 |
1.546–3.440 |
<0.0001 |
1.890 |
1.202–2.973 |
0.006 |
|
ER status | ||||||
| Positive | 1 | — | — | 1 | — | — |
| Negative | 2.411 | 1.837–3.165 | <0.0001 | 2.695 | 1.993–3.644 | <0.0001 |
| Unknown |
1.011 |
0.825–1.239 |
0.917 |
1.272 |
0.964–1.680 |
0.089 |
|
Treatment therapy | ||||||
| Tam | 1 | — | — | 1 | — | — |
| AI | 1.922 | 1.258–2.937 | 0.003 | 1.693 | 1.084–2.644 | 0.021 |
| Mix |
4.893 |
4.077–5.873 |
<0.0001 |
4.606 |
3.792–5.594 |
<0.0001 |
|
Charlson's index | ||||||
| 0–2 | 1 | — | — | 1 | — | — |
| 3–5 | 1.028 | 0.833–1.270 | 0.795 | 1.131 | 0.913–1.401 | 0.260 |
| 6+ |
1.048 |
0.839–1.309 |
0.682 |
1.165 |
0.929–1.462 |
0.185 |
|
Delay | ||||||
| ⩽6 months | 1 | — | — | 1 | — | — |
| >6 months | 1.864 | 1.509–2.303 | <0.0001 | 1.360 | 1.070–1.727 | 0.012 |
Abbreviations: AI=aromatase inhibitor; CI=confidence interval; ER=oestrogen receptor; HR=hazards ratio; SIMD=Scottish Index of Multiple Deprivation; Tam=tamoxifen.
a
Cumulative adherence calculated in a separate model.